Free UK Delivery on orders over £49

Loxicom 0.5mg/ml Oral Suspension For Dogs 15ml

Item Number: LOXICOM05

Loxicom 0.5mg/ml Oral Suspension For Dogs 15ml
  • 15ml

    £ 14.55

    Sorry, this product is not currently available to buy. This is likely because of a manufacturer delay. Call us on 01833 641112 for more information. We may also be able to suggest an alternative.

Total: £0.00

Choose quantity to add to basket

 

 


Browse other products from the Loxicom product range

Description

Loxicom Oral for dogs is an oral suspension for dogs contains 0.5mg of meloxicam. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.


Data Sheets

Loxicom 0.5 mg/ml Oral Suspension for Cats Species:Cats

Therapeutic indication:Pharmaceuticals: Anti-inflammatory preparations: Oral: Other NSAIDs

Active ingredient:Meloxicam

Product:Loxicom 0.5 mg/ml Oral Suspension for Cats

Product index:Loxicom 0.5 mg/ml Oral Suspension Cats

Qualitative and quantitative composition

Active Substance: Meloxicam 0.5 mg

Excipient: Sodium benzoate 1.5 mg

Pharmaceutical form

Pale yellow oral suspension.

Clinical particulars

Target species

Cats.

Indications for use, specifying the target species

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.

Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in cats.

Contraindications

Do not use in pregnant or lactating cats.

Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients

Do not use in cats less than 6 weeks of age.

Special warnings for each target species

None.

Special precautions for use

Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

Post-operative pain and inflammation following surgical procedures:

In case additional pain relief is required, multimodal pain therapy should be considered.

Chronic musculoskeletal disorders:

Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse reactions (frequency and seriousness)

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. Gastrointestinal ulceration and elevated liver enzymes were reported in very rare cases.

These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

The frequency of adverse reactions is defined using the following convention:

  • very common (more than 1 in 10 animals treated displaying adverse reactions)
  • common (more than 1 but less than 10 animals in 100 animals treated)
  • uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
  • rare (more than 1 but less than 10 animals in 10,000 animals treated)
  • very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
  • Use during pregnancy, lactation or lay

    The safety of the veterinary medicinal product has not been established during pregnancy and lactation, (see Contraindications)

    Interaction with other medicinal products and other forms of interaction

    Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

    Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

    Amounts to be administered and administration route

    Oral use.

    To be administered with food or directly into the mouth.

    Shake well before use.

    Dosage

    Post-operative pain and inflammation following surgical procedures:

    After initial treatment with Loxicom 5 mg/ml Solution for Injection for Dogs and Cats continue treatment 24 hours later with Loxicom 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.

    Acute musculo-skeletal disorders:

    Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and inflammation persist.

    Chronic musculo-skeletal disorders:

    Initial treatment is a single dose of 0.1 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg bodyweight.

    A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

    Dosing Procedure:

    The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose of 0.05 mg meloxicam/kg body weight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required. For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4 times the maintenance volume will be required.

    Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded. The suspension should be given using the Loxicom measuring syringe provided in the package.

    Avoid introduction of contamination during use.

    Overdose (symptoms, emergency procedures, antidotes), if necessary

    Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels. In the case of overdose, adverse reactions are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated.

    Pharmacological particulars

    Pharmacotherapeutic Group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams).

    ATCvet code: QM01AC06

    Pharmacodynamic properties

    Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

    Pharmacokinetic particulars

    Absorption

    If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed. Due to the loading dose, steady is reached after 2 days (48h).

    Distribution

    There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.

    Metabolism

    Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

    Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation.

    Elimination

    Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21 % of the recovered dose is eliminated in urine (2 % as unchanged meloxicam, 19 % as metabolites) and 79 % in the faeces (49 % as unchanged meloxicam, 30 % as metabolites).

    Pharmaceutical particulars

    List of excipients

  • Sodium Benzoate
  • Glycerol
  • Povidone K30
  • Xanthan Gum
  • Disodium Phosphate Dihydrate
  • Sodium Dihydrogen Phosphate Dihydrate
  • Citric Acid Anhydrous
  • Simethicone Emulsion
  • Purified water
  • Incompatibilities

    In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

    Shelf-life

    Shelf-life of the veterinary medicinal product as packaged for sale: 18 months

    Shelf-life after first opening the immediate packaging: 6 months

    Special precautions for storage

    This veterinary medicinal product does not require any special storage conditions.

    Nature and composition of immediate packaging

    The veterinary medicinal product is presented in 5 ml, 15 ml and 30 ml polyethylene screw bottles with HDPE/LDPE child resistant caps. The 1 ml measuring syringe has a kg-body weight scale for cats (0.5 to 10 kg).

    Not all pack sizes may be marketed.

    Special precautions for the disposal of unused veterinary medicinal product or waste material derived from the use of such products

    Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

    Marketing Authorisation Holder (if different from distributor)

    Norbrook Laboratories (Ireland) Limited, Rossmore Industrial Estate, Monaghan, Ireland

    Marketing Authorisation Number

    UK(GB): Vm 02000/5000

    UK(NI): EU/2/08/090/009, EU/2/08/090/027, EU/2/08/090/028

    Significant changes

    Date of the first authorisation or date of renewal

    10/02/2009

    Date of revision of the text

    Detailed information on this veterinary medicinal product is available on the website of the European

    Medicines Agency http://www.ema.europa.eu/.

    January 2019

    Any other information

    Nil.

    Legal category

    Legal category:POM-V

    GTIN

    GTIN description:Loxicom 0.5mg/ml Oral Cats 5ml

    GTIN:5023534012986

    GTIN description:Loxicom 0.5mg/ml Oral 15ml

    GTIN:5023534004677

    Delivery

    Shipping charges mainland UK zone1

    ValueWeightDelivery Charge
    Over £49.00Any WeightFREE
    Under £49.00No weight limit£4.50
    Under £49.00Under 250g£2.99

    Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available.

    NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.

    Estimated "Usually shipped in" information is shown against most products

    Overseas orders

    Postage outside of the UK is from £4.50

    Prescription Items

    Prescription items will be sent on receipt of a valid signed and dated prescription.

    Pick up

    We offer a pickup service for orders placed over the phone.

    Please ring us on 01833 641112 for more information.

    Refrigerated Items

    Refrigerated items will be sent by carrier or Royal Mail with coolpacks unless you pay for a premium for a refrigerated delivery. We will contact you prior to despatch for your instructions.

    Returns

    We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email [email protected] to obtain a returns number.

    *Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.

    Frequently Asked Questions

    If treatment is effective after 4 days should it be discontinued.

    Please speak to the prescribing veterinary surgeon

    Ask Question

    Ask a question about Loxicom 0.5mg/ml Oral Suspension For Dogs 15ml


    Reviews